OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	147
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	116
Development and testing of a polygenic risk score for breast cancer aggressiveness	94
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	91
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	84
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	79
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	76
Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy	74
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	74
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	70
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	66
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	66
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	65
Patient-level proteomic network prediction by explainable artificial intelligence	63
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	62
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	56
The dynamic immune behavior of primary and metastatic ovarian carcinoma	54
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	52
Interferon signaling and ferroptosis in tumor immunology and therapy	50
Barriers and opportunities in pancreatic cancer immunotherapy	50
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	47
Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer	47
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma	46
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients	46
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells	45

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	45
An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading	45
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	42
Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis	39
Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer	39
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer	38
Targeting Nrf2/PHKG2 axis to enhance radiosensitivity in NSCLC	38
A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types	38
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab	38
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays	37
Stage-dependent spatial distribution and prognostic value of CD8+ tissue-resident memory T cells in NSCLC	37
Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics	37